Showing results (641-650 of 1,395) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|May 9, 2024
Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal CancersErika Belmont, Varun V Bansal, Mahmoud M G Yousef, et al.
JCO Precision Oncology|May 9, 2024
Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung CancerHyojin Kim, Seokhwi Kim, Sangjoon Choi, et al.
JCO Precision Oncology|November 9, 2023
Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic CancerIfeanyichukwu Ogobuiro, Yasmine Baca, Jennifer R Ribeiro, et al.
JCO Precision Oncology|October 5, 2023
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian CancerLinda R Duska, Dmitriy Zamarin, Erica Hamilton, et al.
JCO Precision Oncology|September 28, 2023
Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical OutcomesPashtoon Murtaza Kasi, Leslie A Bucheit, Jiemin Liao, et al.
JCO Precision Oncology|October 7, 2024
Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAF/NRAS Wild-Type Melanoma (TraMel-WT)Gil Awada, Iris Dirven, Julia Katharina Schwarze, et al.
JCO Precision Oncology|October 11, 2024
Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board DiscussionMaria Fatteh, Jaime Wehr, Katerina Karaindrou, et al.
JCO Precision Oncology|September 30, 2024
Tumor Characteristics Associated With Preoperatively Detectable Tumor-Informed Circulating Tumor DNA in Patients With Renal Masses Suspicious for Renal Cell CarcinomaReuben Ben-David, Parissa Alerasool, Hitasha Kalola, et al.
JCO Precision Oncology|September 30, 2024
Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer PatientsKarin Holmsten, Gottfrid Sjödahl, Johan Abrahamsson, et al.
JCO Precision Oncology|September 30, 2024
Using a Polygenic Risk Score to Improve the Risk Prediction of Non-Small Cell Lung Cancer in TaiwanPo-Hsin Lee, I-Chieh Chen, Yi-Ming Chen, et al.
Pageof 140